Showing results (51-60 of 1,983) with videos related to

Sort By:
Pageof 199
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 12, 2026
Epidemiology, early detection, and management of breast cancer in China: A comprehensive reviewHangcheng Xu, Binghe Xu
Breast Cancer (Dove Medical Press)|March 4, 2021
Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese PerspectivePeng Yuan, Binghe Xu
Frontiers of Medicine|August 14, 2020
Progress in systemic therapy for triple-negative breast cancerHongnan Mo, Binghe Xu
Cancer Biology & Medicine|May 5, 2023
Combined chemo-endocrine therapy as a potential new option for HR+/HER2- advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbineXue Wang, Jian Yue, Yikun Kang, et al.
Thoracic Cancer|November 8, 2023
Efficacy of everolimus-based therapy in advanced triple-positive breast cancer: Experience from three cancer centers in ChinaYujing Tan, Hanfang Jiang, Fei Ma, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|February 19, 2016
[Efficacy and safety of cisplatin plus capecitabine for patients with metastatic triple negative breast cancer progressing after anthracycline and taxane treatment]Qiao Li, Binghe Xu, Qing Li, et al.
Oncotarget|September 8, 2016
Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cellsXiuwen Guan, Fei Ma, Suyan Liu, et al.
Cancer|June 23, 2015
Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trialJiayu Wang, Binghe Xu, Peng Yuan, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|January 28, 2016
[Efficacy and toxicity of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes]Feng Du, Peng Yuan, Yang Luo, et al.
Frontiers in Oncology|August 1, 2020
Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional DosageXiuwen Guan, Fei Ma, Xiaoying Sun, et al.
Pageof 199